Loading...

PE anti-mouse CD45.1 Antibody

Pricing & Availability
Clone
A20 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5.1, LCA
Isotype
Mouse (A.SW) IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
A20
SJL (solid line) and C57BL/6 (broken line) splenocytes stained with A20 PE
  • A20
    SJL (solid line) and C57BL/6 (broken line) splenocytes stained with A20 PE
Compare all formats See PE spectral data
Cat # Size Price Save
110707 50 µg ¥17,600
110708 200 µg ¥37,210
Description

CD45.1 is an alloantigen of CD45, expressed by Ly5.1 bearing mouse strains (e.g., RIII, SJL/J, STS/A, DA). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in mice that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell types. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
SJL mouse thymocytes and splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD45.1 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The A20 antibody does not react with leukocytes or mouse cells expressing the CD45.2 alloantigen. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation3, in vitro blocking of B cell responses1,2, immunohistochemical staining of frozen sections: OCT embedded7 and acetone-fixed4-6 (direct immunofluorescence detection with fluorochrome conjugated A20 was used in (5) and (6)).

Application References

(PubMed link indicates BioLegend citation)
  1. Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block)
  2. Yakura H, et al. 1986. J. Immunol. 136:2729. (Block)
  3. Shen FW, et al. 1986. Immunogenetics 24:146. (IP)
  4. Suzuki K, et al. 2000. Immunity 13:691. (IHC-F)
  5. Werner N, et al. 2002. Arterioscler. Thromb. Vasc. Biol. 22:1567. (IHC-F)
  6. Lessner SM, et al. 2002. Am. J. Pathol. 160:2145. (FC, IHC-F)
  7. Chen CC, et al. 2005. P. Natl. Acad. Sci. USA 102:11408 (IHC-F)
  8. Pascal V, et al. 2007. J. Immunol. 179:1751. (FC)
  9. Mende I, et al. 2006. Blood 107:1383. (IHC-F, FC)
  10. Phan TG, et al. 2007. Nature Immunol. 8:992. (FC)
  11. Wither DR, et al. 2009. J. Immunol. 183:5079. PubMed
  12. Pascal V, et al.2007. J. Immunol. 179:1751. PubMed
  13. Lee SW, et al. 2009. J. Immunol. 182:6753. PubMed
  14. Takada K, et al. 2009. J. Exp Med. 206:2253. PubMed
  15. Beamer CA, et al. 2007. Am. J. Respir. Cell. Mol. Biol. 37:729. (FC) PubMed
  16. Li LX, et al. 2010. J. Immunol. 184:1728. PubMed
  17. Hosoi A, et al. 2008. Cancer Res. 68:3941. (FC) PubMed
  18. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  19. Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations
  1. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  2. Weiberg D, et al. 2018. PLoS One. 13:e0205247. PubMed
  3. Takihara Y, et al. 2022. Commun Biol. 5:776. PubMed
  4. Miranda K, et al. 2022. iScience. 25:104994. PubMed
  5. Albayrak E, et al. 2022. J Cell Biochem. 123:2009. PubMed
  6. McAlpine CS, et al. 2022. J Exp Med. 219: . PubMed
  7. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  8. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  9. De Giovanni M, et al. 2022. Cell. 185:815. PubMed
  10. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  11. Kozlovski S, et al. 2023. Front Immunol. 13:1041552. PubMed
  12. Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed
  13. Houlder E, et al. 2023. Nat Commun. 14:1863. PubMed
  14. Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed
  15. McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed
  16. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  17. Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed
  18. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  19. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  20. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
  21. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  22. Sano T, et al. 2021. Cell Reports. 36:109608. PubMed
  23. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  24. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  25. Bromley SK, et al. 2020. Cell Reports. 32(9):108085. PubMed
  26. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  27. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  28. Lechner AJ et al. 2017. Cell stem cell. 21(1):120-134 . PubMed
  29. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  30. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  31. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  32. Mann M, et al. 2018. Cell Rep. 25:2992. PubMed
  33. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  34. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  35. Fumagalli V, et al. 2020. J Exp Med. :217. PubMed
  36. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  37. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  38. Yoshimi A, et al. 2019. Nature. 574:273. PubMed
  39. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  40. Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed
  41. Prasad M, et al. 2021. Front Immunol. 12:644483. PubMed
  42. Tang Y, et al. 2015. Exp Hematol. 43: 554-564. PubMed
  43. Hu Z, et al. 2017. Sci Rep. 7:41558. PubMed
  44. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  45. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  46. Hillel–Karniel C, et al. 2020. Cell Reports. 30(3):807-819.e4.. PubMed
  47. Lissner MM, et al. 2020. Elife. 9:00. PubMed
  48. Kaplan BLF et al. 2018. Current protocols in toxicology. 75:11:00 25. PubMed
  49. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
  50. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  51. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  52. Morales-Mantilla DE, et al. 2022. Elife. 11:. PubMed
  53. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  54. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  55. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  56. Mishra BB, et al. 2017. Nat Microbiol. 2:17072. PubMed
  57. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  58. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  59. Bei T, et al. 2021. Molecules. 26:. PubMed
  60. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  61. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  62. Li C, et al. 2016. Nat Commun. 7:12632. PubMed
  63. Leon-Rico D, et al. 2015. Lab Anim. 49:132. PubMed
  64. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  65. Ma K, et al. 2022. iScience. 25:104347. PubMed
  66. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  67. Jaako P, et al. 2016. Leukemia. 10.1038/leu.2016.159. PubMed
  68. Ulland T, et al. 2016. Nat Commun. 7:13180. PubMed
  69. Winkler ES, et al. 2020. Cell. 182(4):901-918.e18. PubMed
  70. Evrard M et al. 2018. Immunity. 48(2):364-379 . PubMed
  71. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  72. Agrawal M, et al. 2022. Blood. 140:1094. PubMed
  73. Li J, et al. 2011. Dev Comp Immunol. 35:872. PubMed
  74. Pfau S, et al. 2016. Genes Dev. 30: 1395 - 1408. PubMed
  75. Danzer H, et al. 2020. Elife. 9:00. PubMed
  76. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  77. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  78. Kwok I, et al. 2020. Immunity. 53(2):303-318.e5. PubMed
  79. Halvarsson C, et al. 2019. Antioxid Redox Signal. 31:211. PubMed
  80. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  81. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  82. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  83. Waldman MM, et al. 2022. Front Immunol. 13:856977. PubMed
  84. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  85. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  86. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  87. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
RRID
AB_313496 (BioLegend Cat. No. 110707)
AB_313496 (BioLegend Cat. No. 110708)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets of the CD45.1 strain of mice

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45.1 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account